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ABSTRACT
Aldose reductase (AR) is an enzyme devoted to cell detoxification and at the same time is strongly
involved in the aetiology of secondary diabetic complications and the amplification of inflammatory phe-
nomena. AR is subjected to intense inhibition studies and dimethyl sulfoxide (DMSO) is often present in
the assay mixture to keep the inhibitors in solution. DMSO was revealed to act as a weak but well detect-
able AR differential inhibitor, acting as a competitive inhibitor of the L-idose reduction, as a mixed type of
non-competitive inhibitor of HNE reduction and being inactive towards 3-glutathionyl-4-hydroxynonanal
transformation. A kinetic model of DMSO action with respect to differently acting inhibitors was analysed.
Three AR inhibitors, namely the flavonoids neohesperidin dihydrochalcone, rutin and phloretin, were used
to evaluate the effects of DMSO on the inhibition studies on the reduction of L-idose and HNE.
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Introduction
Since its synthesis almost 150 years ago1, dimethyl sulfoxide
(DMSO) has been proved to be a versatile molecule capable of
accomplishing a variety of functions. The molecule has an incred-
ible number of different uses due to its particular chemicophysical
features2,3, chemical reactivity4, pharmacological effects5–9 and
true or presumed therapeutic properties10,11.
Since DMSO is a polar aprotic solvent, it can dissolve both
polar and hydrophobic compounds. In addition, as it can be mixed
with water as well as with a number of organic solvents, it has
been used as a vehicle for the delivery of various molecules in cul-
tured cells and in in vivo experiments12–15. DMSO has often been
used as a solvent for hydrophobic molecules to investigate their
effects on aqueous media. Thus, many enzymes have been charac-
terised for substrate specificity and susceptibility to inhibition
using DMSO. Its ability to both activate and inhibit enzyme activity
in vitro and in situ has also been reported16–19. When a molecular
species, not necessarily connected to the enzymatic reaction, is
present in the assay mixture, its effect should be ascertained and
if necessary its concentration must be kept constant when other
parameters (i.e. inhibitors and/or substrate concentrations) are var-
ied. However, this good experimental practice, which should be
adopted irrespectively of the known effects of the solvent, may be
hindered as the concentration of DMSO in the assay is often
undefined or indeterminable, or appears to change depending on
the concentration of the inhibitor20–26.
Aldose reductase (AR), since its involvement in the onset of dia-
betic complications, has been the subject of intense study aimed
at finding valuable inhibitors to control its activity27,28. Such stud-
ies often entail the use of DMSO in order to ensure the
solubilisation of inhibitory molecules in the assay mixture. DMSO
has also been used as a vehicle to enable AR inhibitors (ARIs) to
enter target cells12. A recent new approach in the AR inhibition
deals with the search of aldose reductase differential inhibitors
(ARDIs), which should act depending on the substrate AR is work-
ing on, thus blocking the deleterious action of the enzyme and
preserving its detoxifying action29,30.
This study on ARI shows evidence of a differential inhibitory
action exerted by DMSO on the AR activity and examines its influ-
ence on the kinetic characterisation of AR inhibitors.
Materials and methods
Materials
Bovine serum albumin (BSA), D,L-dithiothreitol (DTT), D,L-glyceral-
dehyde (GAL), DMSO, EDTA, were purchased from Sigma-Aldrich
(Saint Louis, MO). NADPH and L-idose were supplied by
Carbosynth (Compton, England); YM10 ultrafiltration membranes
were obtained from Merck-Millipore (Darmstadt, Germany); neo-
hesperidin dihydrochalcone (NHDC), rutin and phloretin were
obtained from Extrasynthese (Lyon, France). All other chemicals
were of reagent grade.
Assay of aldose reductase
The AR activity was determined at 37 C as previously described31,
following the decrease in absorbance at 340 nm due to NADPH
oxidation (e340¼ 6.22mM1cm1) through a Biochrom Libra S60
spectrophotometer (Biochrom, Cambridge, United Kingdom). The
standard assay mixture contained a 0.25M sodium phosphate
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buffer pH 6.8, 0.18mM NADPH, 0.4M ammonium sulphate, 0.5mM
EDTA and 4.7mM GAL. One unit of enzyme activity is the amount
that catalyses the conversion of 1mmol of substrate/min in the
above assay conditions. These assay conditions were also adopted
to assess the effectiveness of inhibitors when L-idose, trans-4-
hydroxy-2,3-nonenal (HNE), or 3-glutathionyl-4-hydroxynonenal
(GSHNE) was used as a substrate instead of GAL.
Purification of human recombinant AR
The human recombinant AR (hAR) was expressed and purified as
previously described32. The purity of the final enzyme preparation
was assessed by SDS-PAGE33 and gels were stained with silver
nitrate34, which showed a single band corresponding to a molecu-
lar weight of approximately 34 kDa. The specific activity of purified
hAR was 5.3 U/mg. The purified enzyme was stored at 80 C in a
10mM sodium phosphate buffer pH 7.0 containing 2mM DTT and
30% (w/v) glycerol. Before use, the enzyme was extensively dia-
lysed against a 10mM sodium phosphate buffer pH 7.0.
Other methods
The protein concentration was determined according to
Bradford35, using BSA as a standard protein. HNE was prepared as
previously described36. GSHNE was prepared as previously
described37 by incubation of GSH and HNE, monitoring the time
course of GSH consumption. The residual GSH was determined as
previously described38.
Statistical analysis was performed using the two-way ANOVA
test operated with GraphPad version 6.0 software (GraphPad
Software, La Jolla, CA).
Results and discussion
DMSO as differential inhibitor of hAR
The ability of DMSO to affect AR activity was evaluated using L-
idose and HNE, two of the substrates routinely used to define the
inhibitory features of ARDIs29,30,39. As shown in Figure 1, DMSO
shows a competitive inhibition towards L-idose reduction and a
mixed type of inhibition towards HNE reduction. In the case of
L-idose as substrate, an inhibitory constant Ki (dissociation con-
stant of the EI complex) of 235± 17mM was determined, while for
HNE a Ki of 266 ± 7mM and a K 0i (dissociation constant of the ESI
complex) of 378± 24mM were measured. Although the overall
inhibitory power on the two different reactions appears to be
essentially the same, DMSO basically behaves as a differential
inhibitor, since it discriminates between the two different sub-
strates undergoing reduction. The effect of DMSO was also tested
on GSHNE, an HNE derivative recognised as a substrate by AR,
whose reduction product is known to elicit the inflammation
response through the activation of the NF-kB cascade40. In this
case, no effect of interference on the enzyme activity was
observed up to 100mM of DMSO in the assay mixture in the pres-
ence of different substrate concentrations. Similarly, no effect of
DMSO was evident on the reduction of GAL catalysed by AR.
In vitro effect of DMSO in the AR inhibition study
In order to evaluate the possible influence of DMSO in identifying
ARDIs, the possibility that an ARI acts differently on the reduction
of different substrates was also considered. Thus, three different
ARIs, namely the flavonoids neohesperidin dihydrochalcone
(NHDC), rutin and phloretin, were used to evaluate the effect of
DMSO in the assay mixture when the inhibition features of these
molecules were evaluated in the reduction of either L-idose or
HNE. This experimental approach was possible due to the solubil-
ity of the above inhibitors in 0.7% (v/v) methanol (approximately
0.17M). At this concentration, the methanol in the enzyme assay
mixture did not affect the AR activity (an inhibition less than 5%
was observed) in the range of substrate concentrations of
0.4–4mM and 40–110 mM for L-idose and HNE, respectively.
Figure 2 reports the results of a typical kinetic study aimed at
determining the dissociation constants Ki and K 0i of the binary
(enzyme:inhibitor) and the ternary (enzyme:substrate:inhibitor)
complexes, respectively, for NHDC, used as an inhibitor of the
reduction of both L-idose and HNE. The same analysis was per-
formed with phloretin and rutin (data not shown). Table 1 reports
the Ki and K 0i values of the three inhibitors measured for the
reduction of both L-idose and HNE. While phloretin showed essen-
tially the same inhibitory activity towards both substrates, rutin
and NHDC exerted a modest, differential inhibitory action on
L-idose reduction with respect to HNE reduction. In fact, both rutin
and NHDC behave as mixed inhibitors of AR in the presence of
L-idose, and as uncompetitive inhibitors in the presence of HNE.
While for rutin, the ability to interact with the AR:L-idose complex
prevailed, NHDC appeared to preferentially bind the free enzyme.
To evaluate the effect of DMSO on the inhibitory action of the
three flavonoids, the same analytical approach was performed for
the three inhibitors acting on both L-idose and HNE reduction,
Figure 1. Effect of DMSO on aldose reductase activity. Inhibition data of DMSO on AR are reported in double reciprocal plots. Panel A: AR activity was determined
using different L-idose concentrations, both in the absence (circle) and in the presence of 40mM (triangle), 100mM (square), and 200mM (diamond) DMSO. Panel B:
AR activity was determined using different HNE concentrations, both in the absence (circle) and in the presence of 100mM (triangle), 200mM (square), and 300mM
(diamond) DMSO.
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with DMSO in different concentrations in the assay mixture. The
values of the apparent Ki and K 0i are again reported in Table 1. In
the case of L-idose reduction, DMSO led to an increase in Ki val-
ues, while K 0i values remained essentially unchanged for all the
three inhibitors. However in terms of HNE reduction, DMSO caused
an increase in K 0i values (approximately twice at the maximal
DMSO concentration) for rutin and NDHC, and a similar increase in
both kinetic inhibition constants for phloretin.
Kinetic models of double inhibition enzymes
In order to explain the effects of the observed interference of
DMSO on the kinetic characterisation of differently acting ARIs, a
kinetic analysis of different inhibition models was considered.
Thus the effects were analysed of a competitive inhibition or a
mixed type of inhibition (as is the case of DMSO towards the
reduction of L-idose or HNE, respectively) on a competitive,
uncompetitive, and mixed type of inhibition of the molecules
under investigation.
The analysis was performed according to a previously
reported double inhibition approach41 considering a simple
mutual exclusion kinetic model (Figure 3) in which both DMSO
(D) and a generic inhibitor of the enzyme (I) behave as mixed
Figure 2. Effect of DMSO on the inhibition of AR by NHDC. Panel A and B: AR activity was determined using different L-idose concentrations in the presence of 0
(circle), 50 (triangle), 100 (square), or 150 (diamond) mM NHDC, both in the absence (Panel A) and in the presence of 100mM DMSO (Panel B). AR activity was deter-
mined using different HNE concentrations, both in the presence of 0 (circle), 50 (triangle), and 100 (square) mM NHDC both in the absence (Panel C) and in the pres-
ence of 200mM DMSO (Panel D).
Table 1. Inhibition constants of neohesperidin dihydrochalcone, rutin and phloretin for the reduction of L-idose, or HNE determined at different DMSO
concentrations.
Ki (mM) Ki0 (mM)
Substrate Inhibitor Inhibition model No DMSO DMSO 40mM DMSO 100mM DMSO 200mM No DMSO DMSO 40mM DMSO 100mM DMSO 200mM
L-idose NHDC Mixed 93 ± 17 114 ± 15 125 ± 16 194 ± 17 292 ± 17 286 ± 53 230 ± 35 283 ± 2
HNE NHDC Uncompetitive – – – – 122 ± 19 134 ± 11 150 ± 22 199 ± 6
L-idose Rutin Mixed 17.8 ± 3.0 20.3 ± 1.1 24.8 ± 3.8 45.6 ± 5.5 9.3 ± 1.1 7.6 ± 1.2 11.7 ± 0.5 12.7 ± 2.0
HNE Rutin Uncompetitive – – – – 9.2 ± 0.9 10.5 ± 2.0 12.8 ± 1.9 16.5 ± 1.9
– – – –
L-idose Phloretin Mixed 66.6þ 5.8 85.4þ 9.0 98.9þ 11.7 120.8þ 43.1 52.5þ 3.8 62.9þ 2.3 50.3þ 4.8 60.9þ 2.1
HNE Phloretin Mixed 60.5þ 7.2 79.0þ 23.5 94.8þ 12.1 106.8þ 12.3 56.5þ 4.5 64.7þ 1.4 73.4þ 7.5 99.5þ 7.3
Figure 3. Kinetic model of mutual exclusion inhibition by DMSO and a generic
inhibitor on the transformation of a generic substrate. See the text for an explan-
ation of the symbols.
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type inhibitors with respect to the AR catalysed reduction of a
generic substrate S.
Thus, the general equation for the initial reaction rate as a
function of the substrate concentration:
v0 ¼ kþ2 ES½ 
taking into account the steady state conditions for the substrate
transformation:
kþ1 E½  S½  ¼ k1 þ kþ2ð Þ ES½ 
the equilibrium conditions for the enzyme targeting by the inhibi-
tors:
KD ¼ E
½  D½ 
ED½  ; KI ¼
E½  I½ 
EI½  ; K
0
D ¼
ES½  D½ 
ESD½  ; K
0
I ¼
ES½  I½ 
ESI½ 
and the mass balance for the enzyme
ET½  ¼ E½  þ ES½  þ ED½  þ EI½  þ ESD½  þ ESI½ 
can be developed into:
v0
ET½  ¼
kþ2
1þ KM
S½  þ KM D
½ 
KD S½  þ
KM I½ 
KI S½  þ
D½ 
K 0D
þ I½ K 0I
in which KM stands for the Michaelis constant. This equation, after
simple algebra, can be represented in the usual form of a rect-
angular hyperbola.
v0 ¼
kþ2 ET½  S½ 
1þ D½ 
K0
D
þ I½ 
K0
I
KM
1þ D½ KDþ
I½ 
KI
1þ D½ 
K0
D
þ I½ 
K0
I
 !
þ S½ 
(1)
This kinetic equation can be then simplified for different combi-
nations of inhibition models referring both to DMSO and to the
tested inhibitors (see Appendix). On the basis of Equation (1), the
effect of DMSO on the kinetic behaviour of some inhibitors was
Figure 4. Simulation of the effect of DMSO on the inhibition of AR by NHDC, rutin, and phloretin. A computer-assisted plot was generated to simulate the effect of
DMSO, described by Equation (1), on the inhibition of AR, using both L-idose (left Panels) and HNE (right Panels) as substrate. The kinetic parameters adopted in the simu-
lation were as follows: i) VMAX and KM for L-idose as substrate were 0.011mM/min and 2.3mM, respectively; ii) VMAX and KM for HNE as substrate were 0.008mM/min
and 0.07mM, respectively; iii) the inhibition kinetic parameters (i.e. Ki and K 'i ) referring to DMSO and to the three tested inhibitors are reported in Table 1. In each panel,
curves 1, 2, and 3 were obtained both in the absence (solid line) and in the presence of 200mM (dashed line) DMSO at the following inhibitor concentrations: NHDC 0,
50, and 100mM, respectively (Panels A and B), rutin 0, 5, and 15mM, respectively (Panels C and D), phloretin 0, 25, and 100mM, respectively (Panels E and F).
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evaluated by computer simulation (Figure 4). The kinetic parame-
ters used in the simulation are those from the above inhibition
kinetic study on DMSO towards both L-idose and HNE reduction
(Figure 1) together with those referring to the three ARIs charac-
terised above, which act in the absence of DMSO on either L-idose
or HNE reduction (Table 1). Thus, Panels A, C, and E on the left in
Figure 4 refer to the effect of DMSO (acting as a competitive
inhibitor) on the reduction of L-idose in the presence of mixed
type inhibitors, i.e. NDHC, rutin and phloretin, respectively (see
Appendix, section 3). Similarly, Panels B, D and F on the right in
Figure 4 refer to the effect of DMSO (acting as a mixed inhibitor)
on the reduction of HNE in the presence of uncompetitive inhibi-
tors (i.e. NDHC and rutin, Panels B and D, respectively), as depicted
in the Appendix (section 4), and in the presence of a mixed type
inhibitor (i.e. phloretin, Panel F), as reported in the general inhib-
ition model (Figure 3 and Equation (1)).
Through this approach, using different DMSO concentrations
(namely 40, 100, and 200mM), it was possible to estimate the the-
oretical overall effect of DMSO on the apparent efficiency and on
the inhibitors model of action (Table 2), and compare these results
with the parameters in Table 1. This shows how the measured
parameters are satisfactorily verified by the theoretical predictions
emerging from the general kinetic model in Figure 3. In addition,
the apparent linear fitting of the experimental data on double
reciprocal plots suggest the occurrence of a double inhibition by
the DMSO and the tested inhibitor, devoid of the simultaneous
presence of both molecular species in the enzyme.
Conclusions
These results highlight the need to keep the solvent rigorously
constant in the enzyme assay mixture, and more importantly, sug-
gest that the contribution of the DMSO used as solvent in AR
inhibition studies may be not negligible in determining both the
binding efficiency and the targeting model of the inhibitor.
Regarding the importance of the DMSO effect as a solvent in
inhibition studies, it is worth considering that when the effective-
ness of the inhibitor under investigation is high, the low concen-
tration needed to define the inhibition parameters may minimise
the interference of the solvent. This is both due to mechanistic
reasons, linked to the comparison of the kinetic parameters of the
solvent and the inhibitor, and because the reduced level of the
solvent needed to maintain the inhibitor in solution at low con-
centrations. However, when a significant level of the solvent is
required to keep the molecule in solution, especially when the
strength of the inhibitor is not extraordinarily high, the effect of
the solvent cannot be disregarded. This is possibly the case in the
search and characterisation of AR differential inhibitors30. In fact,
since these molecules are required in order to inhibit the enzyme
depending on the substrate is undergoing to enzymatic
transformation, their potency may not be very high. All this simply
emerges viewing DMSO as an external additional independent fac-
tor with respect to the mechanism of the enzymatic reaction and
to its inhibition.
More concerns may arise when considering the possible partici-
pation of the solvent in the targeting event of the enzyme by the
inhibitor. In fact, the features of the inhibitor may be strongly
affected by the kinetics and thermodynamic restrictions of the
desolvation step of the inhibitor from DMSO to the enzyme inter-
active site. This kind of unavoidable problem, which generally
occurs in poorly water-soluble ligand studies, has no easy solution.
Only a comparative study of the specific inhibitor in different sol-
vents or solvent cocktails might provide an insight into the role of
DMSO in the effectiveness and inhibition mode of an inhibitory
molecule.
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Appendix
On the basis of the same relationships and restrictions adopted in
Figure 3 (see text), and taking into account the appropriate
enzyme mass balance, the general kinetic equation:
v0 ¼ kþ2 ES½ 
can be reformulated, considering the combination of different
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inhibition models of action of DMSO (D) and a generic inhibitor (I)
with respect to the transformation of the substrate S:
1) Double inhibition model with both DMSO and I acting as
competitive inhibitors
From the enzyme mass balance:
ET½  ¼ E½  þ ES½  þ ED½  þ EI½ 
it follows
v0 ¼ kþ2 ET½  S
½ 
KM 1þ D½ KD þ
I½ 
KI
 
þ S½ 
2) Double inhibition model with DMSO acting as competitive
inhibitor and I acting as uncompetitive inhibitor
From the enzyme mass balance:
ET½  ¼ E½  þ ES½  þ ED½  þ ESI½ 
it follows
v0 ¼
kþ2 ET½  S½ 
1þ I½ 
K0
I
KM
1þ D½ KD
1þ I½ 
K0
I
 !
þ S½ 
3) Double inhibition model with DMSO acting as competitive
inhibitor and I acting as mixed inhibitor
From the enzyme mass balance:
ET½  ¼ E½  þ ES½  þ ED½  þ EI½  þ þ ESI½ 
it follows:
v0 ¼
kþ2 ET½  S½ 
1þ I½ 
K0
I
KM
1þ D½ KDþ
I½ 
KI
1þ I½ 
K0
I
 !
þ S½ 
4) Double inhibition model with DMSO acting as mixed
inhibitor and I acting as uncompetitive inhibitor
From the enzyme mass balance:
ET½  ¼ E½  þ ES½  þ ED½  þ ESD½  þ ESI½ 
it follows
v0 ¼
kþ2 ET½  S½ 
1þ D½ 
K0
D
þ I½ 
K0
I
KM
1þ D½ KD
1þ D½ 
K0
D
þ I½ 
K0
I
 !
þ S½ 
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